.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,369,184

« Back to Dashboard

Claims for Patent: 4,369,184

Title: 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives
Abstract:Novel 1-(cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives, bearing in the 4-position of the cyclohexyl ring a cyano group and an aryl moiety, said compounds displaying useful antihistaminic properties.
Inventor(s): Stokbroekx; Raymond A. (Beerse, BE), Luyckx; Marcel G. M. (Geel, BE), Willems; Joannes J. M. (Turnhout, BE)
Assignee: Janssen Pharmaceutica N.V. (Beerse, BE)
Application Number:06/191,631
Patent Claims: 1. A chemical compound having the formula ##STR18## the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein:

R.sup.1 is a member selected from the group consisting of hydrogen and lower alkyl;

R is a member selected from the group consisting of hydroxy, lower alkyloxy, aryllower alkyloxy, aryloxylower alkyloxy, lower alkyloxylower alkyloxy, aminolower alkyloxy, mono- and di(lower alkyl)amino lower alkyloxy, (1-pyrrolidinyl)-, (1-piperidinyl)- and (4-morpholinyl)lower alkyloxy, amino, aryllower alkyl amino, mono- and di(lower alkyl)amino, 1-pyrrolidinyl, 1-piperidinyl and 4-morpholinyl; and

Ar.sup.1 and Ar.sup.2 are each independently selected from the group consisting of aryl, thienyl and pyridinyl;

wherein aryl, as used in the definitions of R, Ar.sup.1 and Ar.sup.2, is a membere selected from the group consising of phenyl and substituted phenyl, said substituted phenyl having from 1 to 3 substituents each independently selected from the group consisting of lower alkyl, lower alkyloxy, halo, nitro, amino, cyano, carboxyl, lower alkyloxy carbonyl, mono- and di(lower alkyl)aminocarbonyl and trifluoromethyl.

2. A chemical compound selected from the group consisting of 1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-4-piperidinecar boxylic acid, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof.

3. An antihistaminic pharmaceutical composition comprising an inert carrier material and as an active ingredient an effective antihistaminic amount of a chemical compound selected from the group consisting of a 1-(cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivative having the formula ##STR19## the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein:

R.sup.1 is a member selected from the group consisting of hydrogen and lower alkyl;

R is a member selected from the group consisting of hydroxy, lower alkyloxy, aryllower alkyloxy, aryloxylower alkyloxy, lower alkyloxylower alkyloxy, aminolower alkyloxy, mono- and di(lower alkyl)aminolower alkyloxy, (1-pyrrolidinyl)-, 1-(piperidinyl)- and (4-morpholinyl)lower alkyloxy, amino, aryllower alkylamino, mono- and di(lower alkyl)amino, 1-pyrrolidinyl, 1-piperidinyl and 4-morpholinyl; and

Ar.sup.1 and Ar.sup.2 are each independently selected from the group consisting of aryl, thienyl and pyridinyl;

wherein aryl, as used in the definitions of R, Ar.sup.1 and Ar.sup.2, is a member selected from the group consisting of phenyl and substituted phenyl, said substituted phenyl having from 1 to 3 substituents each independently selected from the group consisting of lower alkyl, lower alkyloxy, halo, nitro, amino, cyano, carboxyl, lower alkyloxy carbonyl, mono- and di(lower alkyl)aminocarbonyl and trifluoromethyl.

4. An antihistaminic pharmaceutical composition comprising an inert carrier material and as an active ingredient an effective antihistaminic amount of a chemical compound selected from the group consisting of 1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-4-piperidinecar boxylic acid, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof.

5. A method to prevent the release of histamine in warm-blooded animals which comprises the systemic administration to said animals of an effective antihistaminic amount of a chemical compound selected from the group consisting of a 1-(cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivative having the formula ##STR20## the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein:

R.sup.1 is a member selected from the group consisting of hydrogen and lower alkyl;

R is a member selected from the group consisting of hydroxy, lower alkyloxy, aryllower alkyloxy, aryloxylower alkyloxy, lower alkyloxylower alkyloxy, aminolower alkyloxy, mono- and di(lower alkyl)aminolower alkyloxy, (1-pyrrolidinyl)-, (1-piperidinyl)- and (4-morpholinyl)lower alkyloxy, amino, aryllower alkylamino, mono- and di(lower alkyl)amino, 1-pyrrolidinyl, 1-piperidinyl and 4-morpholinyl; and

Ar.sup.1 and Ar.sup.2 are each independently selected from the group consisting of aryl, thienyl and pyridinyl;

wherein aryl, as used in the definitions of R, Ar.sup.1 and Ar.sup.2, is a member selected from the group consisting of phenyl and substituted phenyl, said substituted phenyl having from 1 to 3 substituents each independently selected from the group consisting of lower alkyl, lower alkyloxy, halo, nitro, amino, cyano, carboxyl, lower alkyloxycarbonyl, mono- and di(lower alkyl)aminocarbonyl and trifluoromethyl.

6. A method to prevent the release of histamine in warm-blooded animals which comprises the systemic administration to said animals of an effective antihistaminic amount of a chemical compound selected from the group consisting of 1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-4-piperidinecar boxylic acid, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof.

7. A chemical compound having the formula ##STR21## the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein:

R.sup.1 is a member selected from the group consisting of hydrogen and lower alkyl;

R is a member selected from the group consisting of hydroxy, lower alkyloxy, aryllower alkyloxy, aryloxylower alkyloxy, lower alkyloxylower alkyloxy, aminolower alkyloxy, mono- and di(lower alkyl)amino lower alkyloxy, (1-pyrrolidinyl)-, (1-piperidinyl)- and (4-morpholinyl)lower alkyloxy, amino, aryllower alkylamino, mono- and di(lower alkyl)amino, 1-pyrrolidinyl, 1-piperidinyl and 4-morpholinyl; and

Ar.sup.1 and Ar.sup.2 are each independently selected from the group consisting of aryl, thienyl and pyridinyl;

wherein aryl, as used in the definitions of R, Ar.sup.1 and Ar.sup.2, is a member selected from the group consisting of phenyl and substituted phenyl, said substituted phenyl having from 1 to 3 substituents each independently selected from the group consisting of lower alkyl, lower alkyloxy, halo, nitro, amino, cyano, carboxyl, lower alkyloxycarbonyl, mono- and di(lower alkyl)aminocarbonyl and trifluoromethyl.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc